Ford’s CEO needs to deliver by next quarter, or we’re moving on from the stock

Ford’s CEO needs to deliver by next quarter, or we’re moving on from the stock


Ford CEO Jim Farley at the company’s Dearborn, Michigan, plant where it’s building the electric F-150 Lightning on April 26, 2022.

CNBC | Michael Wayland

Ford Motor (F) CEO Jim Farley on Friday said the automakers’ messy fourth quarter was a function of its transition to a new business structure that limited production capacity, combined with poor execution. But we remain disappointed in the results, and need to see an increase in profitability to stick with the stock after the next quarter.



Source

The price of menstrual products is skyrocketing from inflation, tariffs
Business

The price of menstrual products is skyrocketing from inflation, tariffs

Always products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina October 29, 2024.  Dado Ruvic | Reuters Rising inflation and ever-changing tariff policies have led to higher prices across store shelves over the past few years, squeezing consumers’ budgets. An often overlooked example: menstrual products. The average price of menstrual […]

Read More
Nissan’s new hybrid is a U.S.-first that mixes EV driving with a gas engine
Business

Nissan’s new hybrid is a U.S.-first that mixes EV driving with a gas engine

Nissan’s logo is illuminated on a prototype of its new all-electric Ariya crossover. Nissan’s Z Proto performance car is reflected in the vehicle’s grille, while a redesigned Nissan Pathfinder SUV sits in the background. Michael Wayland / CNBC Nissan Motor plans to introduce a new type of hybrid to the U.S. market that drives like […]

Read More
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
Business

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

A mini burger, mini fries and mini beer, Clinton Hall’s “Teeny Weeny Mini Meal”, is pictured next to a regular-sized combo on Dec. 8, 2025 in New York City. Approximately one in eight American adults are currently taking drugs from the class of GLP-1 agonists that are now popular for weight loss, according to a […]

Read More